Haematologica (Dec 2018)
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- Meletios A. Dimopoulos,
- Jesus San-Miguel,
- Andrew Belch,
- Darrell White,
- Lotfi Benboubker,
- Gordon Cook,
- Merav Leiba,
- James Morton,
- P. Joy Ho,
- Kihyun Kim,
- Naoki Takezako,
- Philippe Moreau,
- Jonathan L. Kaufman,
- Heather J. Sutherland,
- Marc Lalancette,
- Hila Magen,
- Shinsuke Iida,
- Jin Seok Kim,
- H. Miles Prince,
- Tara Cochrane,
- Albert Oriol,
- Nizar J. Bahlis,
- Ajai Chari,
- Lisa O’Rourke,
- Kaida Wu,
- Jordan M. Schecter,
- Tineke Casneuf,
- Christopher Chiu,
- David Soong,
- A. Kate Sasser,
- Nushmia Z. Khokhar,
- Hervé Avet-Loiseau,
- Saad Z. Usmani
Affiliations
- Meletios A. Dimopoulos
- The National and Kapodistrian University of Athens, Greece
- Jesus San-Miguel
- Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain
- Andrew Belch
- Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada
- Darrell White
- QEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada
- Lotfi Benboubker
- Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France
- Gordon Cook
- St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, UK
- Merav Leiba
- Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
- James Morton
- Icon Cancer Care, South Brisbane, QLD, Australia
- P. Joy Ho
- Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
- Kihyun Kim
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Naoki Takezako
- Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan
- Philippe Moreau
- Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France
- Jonathan L. Kaufman
- Winship Cancer Institute, Emory University, Atlanta, GA, USA
- Heather J. Sutherland
- Leukemia/Bone Marrow Transplant Program, University of British Columbia, Vancouver, Canada
- Marc Lalancette
- CHU de Québec Research Center, Faculty of Medicine, Laval University, Canada
- Hila Magen
- Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel
- Shinsuke Iida
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan
- Jin Seok Kim
- Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea
- H. Miles Prince
- Cabrini Hospital, Epworth HealthCare and Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia
- Tara Cochrane
- Gold Coast University Hospital, Southport, QLD, Australia
- Albert Oriol
- Institut Català d’Oncologia i Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona, Spain
- Nizar J. Bahlis
- University of Calgary, Arnie Charbonneau Cancer Institute, Alberta, Canada
- Ajai Chari
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Lisa O’Rourke
- Janssen Research & Development, LLC, Spring House, PA, USA
- Kaida Wu
- Janssen Research & Development, LLC, Spring House, PA, USA
- Jordan M. Schecter
- Janssen Research & Development, LLC, Raritan, NJ, USA
- Tineke Casneuf
- Janssen Research & Development, Beerse, Belgium
- Christopher Chiu
- Janssen Research & Development, LLC, Spring House, PA, USA
- David Soong
- Janssen Research & Development, LLC, Spring House, PA, USA
- A. Kate Sasser
- Genmab US, Inc, Princeton, NJ, USA
- Nushmia Z. Khokhar
- Janssen Research & Development, LLC, Spring House, PA, USA
- Hervé Avet-Loiseau
- Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
- Saad Z. Usmani
- Levine Cancer Institute/Atrium Health, Charlotte, NC, USA
- DOI
- https://doi.org/10.3324/haematol.2018.194282
- Journal volume & issue
-
Vol. 103,
no. 12
Abstract
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs. 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P
